Tao Pang

Tao Pang

Auto-generated profile, based on publicly available information

Tao Pang

State Key Laboratory of Natural Medicines, New Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2017 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
JKJohn Alimamy Kabba
John Alimamy Kabba
YXYazhou Xu
Yazhou Xu
HCHandson Christian
Handson Christian
WRWenchen Ruan
Wenchen Ruan
KCKitchen Chenai
Kitchen Chenai
TPTao Pang
Tao Pang

10 January 2018 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
YWYunjie Wang
Yunjie Wang
YHYun Huang
Yun Huang
YXYazhou Xu
Yazhou Xu
WRWenchen Ruan
Wenchen Ruan
HWHaojie Wang
Haojie Wang
TPTao Pang
Tao Pang
Aims: Microglia-mediated neuroinflammation plays an important role in focal ischemic stroke, a disorder with no effective therapeutic agents. Since microglial polarization to the M2 phenotype and reduction of oxidative stress are mediated through AMP-activated protein kinase (AMPK) and nuclear factor erythroid 2-related factor 2 (Nrf2) activation, we assessed the dual therapeutic effect of AMPK and Nrf2 activation by a novel neuroprotectant HP-1c in the treatment of ischemic stroke. Results: We developed a novel class of hybrids (HP-1a–HP-1f) of telmisartan and 2-(1-hydroxypentyl)-benzoate (HPBA) as a ring-opening derivative of NBP. The most promising hybrid, HP-1c, exhibited more potent anti-inflammatory and neuroprotective effects in vitro and reduced brain infarct volume and improved neurological deficits in a rat model of transient focal cerebral ischemia when compared with telmisartan alone, NBP alone, or a combination of telmisartan and NBP. HP-1c had a therapeutic window of up to 24 h, ameliorated ischemic cerebral injury in permanent focal cerebral ischemia, and improved motor function. The beneficial effects of HP-1c in ischemic stroke were associated with microglial polarization to the M2 phenotype and reduced oxidative stress. HP-1c also shifted the M1/M2 polarization in a mouse neuroinflammatory model. The anti-inflammatory and anti-oxidative effects of HP-1c were associated with AMPK-Nrf2 pathway activation for neuroprotection. We showed that HP-1c penetrates the brain, has a plasma half-life of around 3.93 h, and has no toxicity in mice. Innovation and Conclusion: Our study results suggest that HP-1c, with dual AMPK- and Nrf2-activating properties, may have potential in further studies as a novel therapy for ischemic stroke. Antioxid. Redox Signal . 28, 141–163.

1 November 2015 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
YXYuan Xu
Yuan Xu
YXYazhou Xu
Yazhou Xu
YWYurong Wang
Yurong Wang
YWYunjie Wang
Yunjie Wang
LHLing He
Ling He
TPTao Pang
Tao Pang

1 March 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
THTailin He
Tailin He
JSJialin Shang
Jialin Shang
CGChenglong Gao
Chenglong Gao
XGXin Guan
Xin Guan
YCYingyi Chen
Yingyi Chen
TPTao Pang
Tao Pang
Ischemic stroke is the second leading cause of death worldwide with limited medications and neuroinflammation was recognized as a critical player in the progression of stroke, but how to control the overactive neuroinflammation is still a long-standing challenge. Here, we designed a novel SIRT6 activator MDL-811 which remarkably inhibited inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages and primary mouse microglia, which were abolished by silencing SIRT6. RNA-seq screening identified the forkhead box C1 (Foxc1) is a key gene evoked by MDL-811 stimulation and is required for the anti-inflammatory effects of MDL-811. We found MDL-811-activated SIRT6 directly interacted with enhancer of zeste homolog 2 (EZH2) and promoted deacetylation of EZH2 which could bind to the promoter of Foxc1 and upregulate its expression to modulate inflammation. Moreover, our data demonstrated that MDL-811 not only ameliorated sickness behaviors in neuroinflammatory mice induced by LPS, but also markedly reduced the brain injury in ischemic stroke mice in addition to promoting long-term functional recovery. Importantly, MDL-811 also exhibited strong anti-inflammatory effects in human monocytes isolated from ischemic stroke patients, underlying an interesting translational perspective. Taken together, MDL-811 could be an alternative therapeutic candidate for ischemic stroke and other brain disorders associated with neuroinflammation.

3 May 2024 in Cell Reports Medicine
Verified
Journal Article
Open access
XGXin Guan
Xin Guan
SZSitong Zhu
Sitong Zhu
JSJinqian Song
Jinqian Song
KLKui Liu
Kui Liu
MLMei Liu
Mei Liu
TPTao Pang
Tao Pang
Neuroinflammation plays a significant role in ischemic injury, which can be promoted by oxidized mitochondrial DNA (Ox-mtDNA). Cytidine/uridine monophosphate kinase 2 (CMPK2) regulates mtDNA replication, but its role in neuroinflammation and ischemic injury remains unknown. Here, we report that CMPK2 expression is upregulated in monocytes/macrophages and microglia post-stroke in humans and mice, respectively. Microglia/macrophage CMPK2 knockdown using the Cre recombination-dependent adeno-associated virus suppresses the inflammatory responses in the brain, reduces infarcts, and improves neurological outcomes in ischemic CX3CR1Cre/ERT2 mice. Mechanistically, CMPK2 knockdown limits newly synthesized mtDNA and Ox-mtDNA formation and subsequently blocks NLRP3 inflammasome activation in microglia/macrophages. Nordihydroguaiaretic acid (NDGA), as a CMPK2 inhibitor, is discovered to reduce neuroinflammation and ischemic injury in mice and prevent the inflammatory responses in primary human monocytes from ischemic patients. Thus, these findings identify CMPK2 as a promising therapeutic target for ischemic stroke and other brain disorders associated with neuroinflammation.

1 July 2021 in Pharmacological Research
Verified
Journal Article
Closed access
YWYunjie Wang
Yunjie Wang
XGXin Guan
Xin Guan
CGCheng-Long Gao
Cheng-Long Gao
WRWenchen Ruan
Wenchen Ruan
SZShunyi Zhao
Shunyi Zhao
TPTao Pang
Tao Pang